Biofrontera Inc., a Delaware corporation, has announced a regulatory issue concerning its listing on The Nasdaq Capital Market. On May 8, 2025, the company received a notification from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2) due to its common stock's closing bid price being below $1.00 per share for 33 consecutive business days. While this notice does not immediately affect the trading of Biofrontera's securities, the company has been granted a 180-day period, until November 5, 2025, to regain compliance by achieving a minimum closing bid price of $1.00 per share for at least 10 consecutive business days. If necessary, Biofrontera may seek additional time to rectify the issue, potentially through a reverse stock split. The company is actively monitoring the situation and exploring options to resolve the deficiency. However, there is no guarantee of regaining compliance or meeting other listing requirements.